Abstract
The duopoly of ten-valent and 13-valent pneumococcal conjugate vaccines: do they differ?
Highlights
In The Lancet Infectious Diseases, Beth Temple and colleagues[1] report on a head-to-head comparison of the immunogenicity, in a low-income to middleincome setting (Vietnam), of the currently licenced tenvalent (PCV10) and 13-valent (PCV13) pneumococcal conjugate vaccines
The two vaccines were administered in a two-dose primary series (2 months and 4 months of age), with a booster dose at 9 months of age (a 2 + 1 schedule), with the primary comparison of immunogenicity between the vaccines being the proportion of recipients with serotype-specific antibody concentrations above the recommended composite putative threshold of protection developed for invasive pneumococcal disease.[2]
PCV10 and PCV13 did not differ in immunogenicity
Summary
In The Lancet Infectious Diseases, Beth Temple and colleagues[1] report on a head-to-head comparison of the immunogenicity, in a low-income to middleincome setting (Vietnam), of the currently licenced tenvalent (PCV10) and 13-valent (PCV13) pneumococcal conjugate vaccines.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
